Clin Cancer Res: Multiple myeloma . . The "high dose" of amine is not loved

For multiple myeloma, high-dose chemotherapy and self-hematopoietic stem cell transplantation (ASCT) are considered standard therapies for the maintenance of amine (10-15 mg/day).
, reducing the dose due to adverse reactions is common, and the mid-dose level of LenMT may be lower over time.
, the dose response during LenMT has not been studied.
This is a multi-center, randomized, open-label clinical trial in which patients with multiple myeloma after ASCT and high doses of lenamin (25 mg/day) consolidation therapy (CT) were randomly assigned to the LenMT 25 mg/day group or 5 mg/day group.
end point is progress-free survival (PFS).
94 patients (with a medium age of 58) in each of the two groups, 22 percent of whom were in Phase 3 of the International Phased System (ISS) and 22 percent were in advanced remission (CR).
PFS and OS were followed by a medium of 46.7 months after random grouping of 25 mg (blue) and 5 mg (green), with the medium doses of 14.5 and 5 mg/day, respectively, and 53% of the dose reduction occurred during CT.
PFS in the high-dose and low-dose groups was 44.8 months and 33.0 months (HR 0.65; 95% CI, 0.44-0.97, respectively; P-0.032), 36% and 23% of patients received strict total remission (optimal remission), and 4-year OS was 79% and 67% (P-0.016), respectively.
blood toxicity, ≥3-level neutral granulocyte reduction and infection were all found in LenMT 25 mg medications and decreased with dose adjustment.
, LenMT doses are associated with efficacy and toxicity.
high probability of a dose reduction during consolidation therapy suggests that a high initial dose should probably not be used.